Search

Your search keyword '"Pasqualoni, Mariangela"' showing total 11 results
Start Over Author "Pasqualoni, Mariangela"
11 results on '"Pasqualoni, Mariangela"'

2. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma

Author

Rossi, Ernesto, Schinzari, Giovanni, Cellini, Francesco, Balducci, Mario, Pasqualoni, Mariangela, Maiorano, Brigida Anna, Fionda, Bruno, Longo, Silvia, Deodato, Francesco, Di Stefani, Alessandro, Peris, Ketty, Gambacorta, Maria Antonietta, Tortora, Giampaolo, Rossi E., Schinzari G. (ORCID:0000-0001-6105-7252), Cellini F. (ORCID:0000-0002-2145-2300), Balducci M. (ORCID:0000-0003-0398-9726), Pasqualoni M., Maiorano B. A., Fionda B., Longo S., Deodato F. (ORCID:0000-0003-1276-5070), Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tortora G. (ORCID:0000-0002-1378-4962), Rossi, Ernesto, Schinzari, Giovanni, Cellini, Francesco, Balducci, Mario, Pasqualoni, Mariangela, Maiorano, Brigida Anna, Fionda, Bruno, Longo, Silvia, Deodato, Francesco, Di Stefani, Alessandro, Peris, Ketty, Gambacorta, Maria Antonietta, Tortora, Giampaolo, Rossi E., Schinzari G. (ORCID:0000-0001-6105-7252), Cellini F. (ORCID:0000-0002-2145-2300), Balducci M. (ORCID:0000-0003-0398-9726), Pasqualoni M., Maiorano B. A., Fionda B., Longo S., Deodato F. (ORCID:0000-0003-1276-5070), Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma. In oligoprogressive melanoma patients with BRAF mutations, target therapy can be combined with loco-regional radiotherapy (RT). However, the association of BRAF/MEK inhibitors and RT needs to be carefully monitored for potential increased toxicity. Despite the availability of some reports regarding the tolerability of RT + target therapy, data on simultaneous RT and BRAFi/MEKi are limited and mostly focused on the BRAFi vemurafenib. Here, we report a series of metastatic melanoma patients who received fractioned RT regimens for oligoprogressive disease in combination with the BRAFi dabrafenib and the MEKi trametinib, which have continued beyond progression. None of the cases developed relevant adverse events while receiving RT or interrupted dabrafenib and trametinib administration. These cases suggest that a long period of dabrafenib/trametinib interruption during radiotherapy for oligoprogressive disease can be avoided. Prospective trials are warranted to assess the efficacy and safety of the contemporary administration of BRAF/MEK inhibitors and radiotherapy for oligoprogressive disease.

Published
2023

3. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response

Author

Pasqualoni, Mariangela, primary, Orlandi, Armando, additional, Palazzo, Antonella, additional, Garufi, Giovanna, additional, Cannizzaro, Maria Chiara, additional, Pontolillo, Letizia, additional, Pannunzio, Sergio, additional, Cutigni, Claudia, additional, Sollena, Pietro, additional, Federico, Francesco, additional, Bria, Emilio, additional, and Tortora, Giampaolo, additional

Published
2023
Full Text
View/download PDF

4. Abstract P2-02-06: Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

Author

Mastrantoni, Luca, primary, Garufi, Giovanna, additional, Monte, Elena Di, additional, Maliziola, Noemi, additional, Pasqualoni, Mariangela, additional, Pontolillo, Letizia, additional, Pannunzio, Sergio, additional, Cannizzaro, Maria Chiara, additional, Bello, Armando Di, additional, Fabi, Alessandra, additional, Palazzo, Antonella, additional, Bria, Emilio, additional, Tortora, Giampaolo, additional, and Orlandi, Armando, additional

Published
2023
Full Text
View/download PDF

5. sj-docx-1-tam-10.1177_17588359231173180 – Supplemental material for Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

Author

Mastrantoni, Luca, Garufi, Giovanna, Di Monte, Elena, Maliziola, Noemi, Pasqualoni, Mariangela, Pontolillo, Letizia, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Di Bello, Armando, Fabi, Alessandra, Palazzo, Antonella, Tortora, Giampaolo, Bria, Emilio, and Orlandi, Armando

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359231173180 for Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials by Luca Mastrantoni, Giovanna Garufi, Elena Di Monte, Noemi Maliziola, Mariangela Pasqualoni, Letizia Pontolillo, Sergio Pannunzio, Maria Chiara Cannizzaro, Armando Di Bello, Alessandra Fabi, Antonella Palazzo, Giampaolo Tortora, Emilio Bria and Armando Orlandi in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

6. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma

Author

Rossi, Ernesto, primary, Schinzari, Giovanni, additional, Cellini, Francesco, additional, Balducci, Mario, additional, Pasqualoni, Mariangela, additional, Maiorano, Brigida Anna, additional, Fionda, Bruno, additional, Longo, Silvia, additional, Deodato, Francesco, additional, Di Stefani, Alessandro, additional, Peris, Ketty, additional, Gambacorta, Maria Antonietta, additional, and Tortora, Giampaolo, additional

Published
2023
Full Text
View/download PDF

7. Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

Author

Mastrantoni, Luca, primary, Garufi, Giovanna, additional, Di Monte, Elena, additional, Maliziola, Noemi, additional, Pasqualoni, Mariangela, additional, Pontolillo, Letizia, additional, Pannunzio, Sergio, additional, Cannizzaro, Maria Chiara, additional, Di Bello, Armando, additional, Fabi, Alessandra, additional, Palazzo, Antonella, additional, Tortora, Giampaolo, additional, Bria, Emilio, additional, and Orlandi, Armando, additional

Published
2023
Full Text
View/download PDF

8. Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis

Author

Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), Tortora G. (ORCID:0000-0002-1378-4962), Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, A., Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, A. M., Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo, Orlandi A. (ORCID:0000-0001-5253-4678), Pontolillo L., Mele C., Pasqualoni M., Pannunzio S., Cannizzaro M. C., Cutigni C., Garufi G., Vellone M. (ORCID:0000-0002-7628-4092), Ardito F. (ORCID:0000-0003-1596-2862), Franceschini G. (ORCID:0000-0002-2950-3395), Cassano A. (ORCID:0000-0002-3311-7163), Giuliante F. (ORCID:0000-0001-9517-8220), Bria E. (ORCID:0000-0002-2333-704X), and Tortora G. (ORCID:0000-0002-1378-4962)

Abstract

The liver represents the first metastatic site in 5–12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45–103) and 15 months (95% CI 11–46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months versus 16 months; HR 0.083, p < 0.0001) and DFI (16 months versus 5 months; HR 0.17, p = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.

Published
2021

9. Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis

Author

Orlandi, Armando, primary, Pontolillo, Letizia, additional, Mele, Caterina, additional, Pasqualoni, Mariangela, additional, Pannunzio, Sergio, additional, Cannizzaro, Maria Chiara, additional, Cutigni, Claudia, additional, Palazzo, Antonella, additional, Garufi, Giovanna, additional, Vellone, Maria, additional, Ardito, Francesco, additional, Franceschini, Gianluca, additional, Sanchez, Alejandro Martin, additional, Cassano, Alessandra, additional, Giuliante, Felice, additional, Bria, Emilio, additional, and Tortora, Giampaolo, additional

Published
2021
Full Text
View/download PDF

10. Abstract P3-05-06: Impact on outcome and response to neoadiuvant chemotherapy in triple negative breast cancer patients and BRCA mutations

Author

Paris, Ida, primary, Rizza, Roberta, additional, Paolillo, Carmela, additional, Carbognin, Luisa, additional, Calegari, Alessandra, additional, Scambia, Giovanni, additional, Bria, Emilio, additional, Capoluongo, Ettore, additional, Masetti, Riccardo, additional, Urbani, Andrea, additional, Pasqualoni, Mariangela, additional, and Santonocito, Concetta, additional

Published
2020
Full Text
View/download PDF

11. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer

Author

Paris, Ida, primary, Cianci, Stefano, additional, Vizzielli, Giuseppe, additional, Fagotti, Anna, additional, Ferrandina, Gabriella, additional, Gueli Alletti, Salvatore, additional, Costantini, Barbara, additional, Cosentino, Francesco, additional, Capoluongo, Ettore, additional, Pasqualoni, Mariangela, additional, and Scambia, Giovanni, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results